EGFR and head and neck squamous cell carcinoma: According to the phase II trials interim results, the objective response rate (ORR) in head and neck squamous cell carcinoma (HNSCC) patients receiving monalizumab and cetuximab (an anti-EGFR blocking mAb) combination therapy was 31%, which was superior to previous data obtained from cetuximab monotherapy.